UNSPSC 51393318: Suloxifen

This classification denotes a bronchodilator with the molecular formula C18H24N2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LD18TA6Q06, chemically known as N,N-diethyl-2-[[oxo(diphenyl)-a6-sulfanylidene]amino]ethanamine but generally known as suloxifen, which bears US NIH Compound Identifier 3084445. European Medicines Agency schedules suloxifen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10757MIG. Most nations schedule suloxifen under HS 29309085 and SITC 51549.

As of Q4 2014, SULOXIFEN remains the US FDA Preferred Term for this commodity. Suloxifen bears US NLM identifiers UMLS ID C2699724 and NCI Concept Code C76575. SMILES: CCN(CC)CCN=S(=O)(C1=CC=CC=C1)C2=CC=CC=C2.

UNSPSC 51393318 Suloxifen is a Commodity code under which state and local governments procure pharmaceutical products and related health-system supplies, though recent solicitations show activity focused on naloxone and drug deactivation systems rather than suloxifen specifically. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to its Community Health Building. The county requires vendors to include all shipping and delivery costs in their proposals, comply with E-Verify and drug-free workplace certifications, maintain workers' compensation and commercial general liability insurance, and accept a three-month probationary period. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmacy prescription programs, soliciting vendor capabilities around direct contracting with self-insured plans and state agencies, value-based pricing models, and product fulfillment strategies outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity under this code spans at least two states. Seminole County's naloxone procurement (due July 26, 2023) represents health department and county community health activity; the Texas HHS Commission's RFI signals state-level pharmacy benefits interest. The mismatch between the code's nominal scope (suloxifen, a specific pharmaceutical compound) and the actual procurement content (naloxone, drug deactivation systems, and direct-to-manufacturer pharmacy programs) suggests either a classification anomaly in the source data or limited recent activity directly aligned with suloxifen itself. Vendors pursuing opportunities under this code should verify classification accuracy in individual solicitations and track both Texas and Florida jurisdictions for emerging health-system pharmaceutical procurement.